Important Updates for Altimmune, Inc. Investors Facing Legal Action
Legal Notice for Altimmune, Inc. Shareholders
Attention investors of Altimmune, Inc. (NASDAQ: ALT), the Gross Law Firm is reaching out to inform shareholders about a class action lawsuit that may affect them. If you purchased shares during a specified period, your participation in this lawsuit may lead to potential recovery.
Key Details of the Lawsuit
Shareholders who acquired shares between August 10, 2023, and June 25, 2025, are encouraged to contact the Gross Law Firm. They will assist you in understanding your rights and potential role as a lead plaintiff. Engaging with the firm is essential, but it is not a prerequisite for recovery.
About the Allegations
The allegations stem from a significant release on June 26, 2025, when Altimmune announced the results of its IMPACT Phase 2b MASH trial concerning Pemvidutide for treating MASH. The complaint suggests that the company inflated expectations about its results, leading to a surprising failure in achieving statistical significance for the trial's primary endpoint focused on fibrosis reduction.
Impact on Stock Prices
On the announcement date, the stock value faced a drastic drop from $7.71 on June 25, 2025, to $3.61, indicating a staggering decline of 53.2%. This price drop accentuates the potential financial implications for current shareholders.
Important Deadlines to Remember
The deadline for filing your notice of participation in this class action is October 6, 2025. It's crucial that shareholders act swiftly to secure their rights and possible recovery from this lawsuit.
Next Steps for Interested Shareholders
Upon registration with the Gross Law Firm as a shareholder from the mentioned timeframe, you’ll receive continuous updates regarding the progress of the case. Being a lead plaintiff may provide additional benefits, but it comes at no cost or obligation.
Why Choose the Gross Law Firm?
The Gross Law Firm is well-known for its dedication to safeguarding investors' rights affected by deceit and misconduct in the business realm. Their commitment focuses on ensuring that corporations uphold ethical standards and corporate governance. They advocate for those who incurred losses through misleading information, aiming to restore investors' financial balance.
Contact Information
If you need to reach out for assistance or have inquiries, you can contact the Gross Law Firm at:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
Frequently Asked Questions
What should I do if I bought shares of Altimmune?
If you purchased shares during the class period from August 10, 2023, to June 25, 2025, contact the Gross Law Firm for more information about your rights.
What are the allegations against Altimmune?
The allegations involve misleading statements about the efficacy of the drug studied in the Phase 2b trial, which led to significant financial losses for investors.
When is the deadline for participation in the lawsuit?
The deadline for participating in the lawsuit is October 6, 2025.
Is there any cost to register for the lawsuit?
No, there is no cost or obligation to participate in the lawsuit.
Who is leading the lawsuit?
The Gross Law Firm is managing the class action lawsuit and has extensive experience in such cases.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
